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Cell Proliferation and Carcinogenesis:
A Brief History and Current View Based
on an IARC Workshop Report
by L. Tomatis
The International Agency for Research on Cancer recently convened a Working Group of
Experts (June 11-18, 1991) to discuss the use of information on carcinogenesis mechanisms in
carcinogenic risk identification. The role of cell proliferation in carcinogenesis was among the
items discussed in detail. It was recognized that cell proliferation is an important mechanistic
aspect for both genotoxic and nongenotoxic carcinogens. It may act at each stage ofthe carcino-
genesis process, altering the size of the pool of cells at risk for a next event. Cell proliferation
was considered to be important, especially as a) an integral part of the process of converting
DNA adducts to mutation, b) an enhancing factor for the mutation frequency by inducing errors
in replication, and c) an important factor in determining dose-response relationships for some
carcinogens. It was also recognized that not all agents that induce cell proliferation are neces-
sarily involved in carcinogenesis; for example, a) not all skin hyperplasia-inducing compounds
are skin tumor promoters, b) agents that induce "regenerative" cell proliferation appear to
have different effects on tumor induction from agents that have a direct mitogenic effect, and c)
the carcinogenic activity ofmany nonmutagenic agents depends on the continuous administra-
tion ofthe agent. In addition, tissues with a high rate ofcell proliferation do not have a higher
risk of developing cancer. Thus, no simple relationship exists between cell proliferation and
carcinogenesis.
The International Agency for Research on Cancer
(IARC) convened an ad hoc Working Group of scien-
tists in Lyon in June 1991, 8 years after the first meet-
ing on the same subject (1), to consider and advise on
the possible use ofmechanistic information in the eval-
uation of carcinogenicity (2,3). One of the outcomes of
the meeting, the proceedings of which are now avail-
able as an IARC Technical Report (2), has been the
updating of the Preamble to the IARC Monographs,
with some guidelines and indications on how to use
mechanistic information in the final qualitative evalua-
tion of carcinogenicity. Information on mechanisms
may play an essential role when there is a need to
extrapolate from experimental data to the human situ-
ation in the absence ofepidemiological data. One could
assume that humans could be the most affected or sus-
ceptible species or the putatively less affected or unaf-
fected species.
International Agency for Research on Cancer, 150 Cours Albert
Thomas, 69372 Lyon, France.
This paper was presented at the Symposium on Cell Proliferation
and Chemical Carcinogenesis that was held January 14-16, 1992, in
Research Triangle Park, NC.
Does cell proliferation modify the carcinogenesis
process? The obvious answer is that there would not
be a carcinogenesis process without cell proliferation
and that cell proliferation is an essential component of
the process. Two other questions would then need to
be answered: Is cell proliferation carcinogenic per se?
Should investigations on cell proliferation be included
in routine tests on chemicals?
The dominant hypothesis today is that neoplastic
development is a multistage progressive process
involving multiple genetic changes. Events and
changes that in the past were predicted in experimen-
tal and epidemiological studies and remained largely
theoretical for decades can now be investigated and
challenged in molecular studies. There has therefore
been a definite, important advancement in our under-
standing of carcinogenesis, in spite of some uncertain-
ties.
Some ofthe initial changes and events ofthe carcino-
genesis process may occur prenatally and/or may
involve the germ cells. The extent of the contribution
of preconceptional events to what is seen in later gen-
erations as predisposition to cancer, or to certain can-
cers, needs to be better defined. The fact that one or
more steps ofthe carcinogenesis process may occur asL. TOMATIS
distant in time as in previous generations adds further
difficulty to correctly assessing risk (4,5).
The possible role of hyperplasia in carcinogenesis
has been discussed for almost a century and a half.
According to the old theory ofirritation as the cause of
cancer, neoplasia was a kind of extension of hyperpla-
sia. As a natural follow-up of his fundamental discov-
ery of cellular pathology, Virchow also held the view,
against the then-prevailing opinion that tumors were
related to discrasia, that tumors mainly originated fol-
lowing the action of local causes (6). Virchow support-
ed the essential role of gross mechanical insults in the
origin of tumors until the end of his life (6). Similar,
although not identical, to the irritation theory was the
traumatic theory of the origin of tumors which
Cohnheim, the most famous pupil of Virchow, was
ready to dismiss (7). Cohnheim supported the hypothe-
sis that tumors originated from undifferentiated
embryonal cells persisting in many adult tissues. The
embryonic character ofthese cells endowed them with
a "marked capacity for proliferation" (7). This is per-
haps the first strong statement about the role ofcellu-
larproliferation in tumordevelopment.
The irritation theory was abandoned when studies
on tumor formation went beyond the interpretations
based on morphological observations alone. Then came
a long series ofstudies on inhibition and augmentation
ofcarcinogenesis. It was shown that agents that stimu-
late or favor cell proliferation were efficient in enhanc-
ing carcinogenesis when acting after initiation. These
were studies ofFriedewald and Rous (8), Mottram (9),
Berenblum (10,11), Berenblum and Shubik (12), Bout-
well (13), and Foulds [(14); see also Slaga et al. (15)].
Tannenbaum showed that caloric restriction had an
inhibiting effect on carcinogenesis acting on the pro-
motion, but not on the initiation of skin carcinogenesis
(16). The conclusion ofall these studies seemed clear: a
stimulation or inhibition of cell proliferation had an
effect only on late stage(s) ofcarcinogenesis, but not on
the early events.
It is generally accepted that increased cell prolifera-
tion, in order to be most effective in enhancing carcino-
genesis, must act either on an already modified cell
population, or in concurrence with an agent causing
specific changes in the cells. Typically, this may occur
when a genotoxic agent is administered at the dose
that also induces considerable cell proliferation in the
target organ. There is indeed definite evidence that
many carcinogens damage cellular DNA and cause cell
proliferation, exhibiting a combined genotoxic and
mitogenic action (17). It is not evident that increased
cell proliferation plays a role in enhancing carcinogene-
sis when it occurs before DNA damage; however,
because of the small risk of spontaneous mutation (an
error in DNA replication occurring for unknown rea-
sons), there will never be a zero probability of initiat-
ingthe process ofcarcinogenesis.
Cell proliferation can be induced following cell necro-
sis and is then called "regenerative" or "compensato-
ry" cell proliferation. Cell proliferation may also be
induced directly by some chemicals without causing
any cell death and is called "mitogen-induced" cell pro-
liferation. It has been claimed, however, that regenera-
tive cell proliferation subsequent to cell necrosis can be
carcinogenic per se, implying that it could have such an
effect on a cell population in which an initiating event
has not occurred. One of the most quoted examples is
that of kidney tumors as a consequence of the a 2g-
globulin nephropathy induced in male rats by a variety
of chemicals (18). The nephropathy is characterized by
tubular cell necrosis and regenerative cell proliferation
in the P2 section ofthe tubules. However, the chemical
1-(aminomethyl) cycloexane acetic acid (gambetin),
which causes typical a 2,u-globulin nephropathy in
male rats, has been reported not to produce renal can-
cer after 2 years of exposure (19). Cell necrosis and
regeneration induced by nephropathy may therefore
be a contributing factor but not a sufficient cause of
neoplasia.
A further indication of the complexity of the rela-
tionships between toxic injury and neoplasia comes
from the review of carcinogenicity results obtained
with chemicals tested by the National Toxicology
Program (20-22). Based on morphological observa-
tions, mutagenic as well as nonmutagenic chemicals
were shown to cause toxic injury in a variety oftissues
without associated neoplastic effects at the same sites
or to cause tumors at sites where no associated toxic
injury was observed.
Chemicals may indeed exert different types of toxic
injury that may not necessarily be related. Forinstance,
asbestos induces asbestosis, which is unrelated to
mesothelioma, vinyl chloride induces acro-osteolysis,
which is unrelated to liver tumors, and a number of
chemicals that cause teratogenicity and carcinogenici-
ty when given prenatally produce teratogenic and car-
cinogenic effects only occasionally at the same target
organ(s).
In several instances it was shown that the carcino-
genic activity ofagents labeled as mitogens depends on
continued administration of the agent and, further-
more, that preneoplastic foci regress when the chemi-
cal exposure is interrupted. A particular case of mito-
genic action is that of hormones, which is related to
receptor-mediated events. The interpretation of this
particular mitogenic action is rendered somewhat
more complicated by the fact that certain environmen-
tal and synthetic chemicals bind to the estrogen and
other receptors and elicit hormonal response.
Furthermore, endocrine organs are susceptible targets
for the action ofgenotoxic carcinogens.
The IARC Working Group of June 1991 (2) recog-
nized that cell proliferation is an important mechanis-
tic aspect for both genotoxic and nongenotoxic carcino-
gens. Cell proliferation may act at each stage of the
carcinogenesis process, altering the size of the pool of
cells at risk for a next event. Cell proliferation was
considered to be a potentially important factor, espe-
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cially as a part of the process of converting DNA
adducts to mutation, as a potential enhancing factor of
the mutation frequency by increasing the number of
DNA errors during replication, and for determining
dose-response relationships for some carcinogens. It
was also recognized that not all agents that induce cell
proliferation are necessarily involved in carcinogene-
sis; for example, a) not all skin hyperplasia-inducing
compounds are skin tumor promoters, b) agents that
induce regenerative cell proliferation appear to have
different effects on tumor induction from agents that
have a direct mitogenic effect, and c) the carcinogenic
activity of many nonmutagenic agents depends on the
continuous administration ofthe agent.
Although it has been proposed that enhanced cell
replication is an enhancing factor in carcinogenesis
either by favoring the expansion of altered cell clones
or by increasing the rate of spontaneous errors in
replication (2,3-25), it is necessary to acquire clearer
and possibly quantifiable knowledge of carcinogenic
mechanisms before cell proliferation per se becomes
incorporated into an overall evaluation ofcarcinogenic-
ity. There are numerous critical issues that have to be
resolved before we can safely use an assessment
approach with data on chemically induced cell prolifer-
ation. We should aim at understanding and quantifying
the actual effects of enhanced cell proliferation and/or
of reduced cell death rate on the number of sponta-
neous mutations. We should also try to clarify whether
there are qualitative differences between DNA dam-
age and repair that occur spontaneously and those
induced by subliminal doses of carcinogens and
whether and to what extent agents that enhance cell
replication also control transformation. A clarification
of the role of cell proliferation in the carcinogenesis
process will help relieve the contradiction with which
we are too often confronted; that is, although we agree
that cancer has a multifactorial origin, we accept that
risk assessments be geared to the effect of a single
agent.
It is therefore essential that the testing ofagents for
carcinogenicity be elaborated and conducted with the
advice and participation of basic scientists, as well as
biostatisticians and epidemiologists. Discussing and
criticizing the results ofcarcinogenicity studies a poste-
nriori and multiplying their elaborated analysis will not
substantially improve the quality of the data and will
only marginally improve their interpretation.
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